Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:alsoKnownAs |
gptkb:lamivudine
|
| gptkbp:approvedBy |
gptkb:FDA
1995 |
| gptkbp:ATCCode |
gptkb:J05AF05
|
| gptkbp:CASNumber |
gptkb:134678-17-4
|
| gptkbp:chemicalFormula |
gptkb:C8H11N3O3S
|
| gptkbp:combines |
gptkb:abacavir
gptkb:zidovudine |
| gptkbp:contraindication |
allergy to lamivudine
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:eliminationHalfLife |
5-7 hours
|
| gptkbp:excretion |
renal
|
| https://www.w3.org/2000/01/rdf-schema#label |
Epivir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits reverse transcriptase
|
| gptkbp:MedlinePlusID |
a697039
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
60825
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache |
| gptkbp:UNII |
2T8Q726O95
|
| gptkbp:usedFor |
HIV infection
chronic hepatitis B |
| gptkbp:WHOModelListOfEssentialMedicines |
true
|
| gptkbp:bfsParent |
gptkb:lamivudine
|
| gptkbp:bfsLayer |
6
|